Palmarumycin P3 Reverses Mrr1-Mediated Azole Resistance by Blocking the Efflux Pump Mdr1-Reference-Cited by-同舟云学术

Palmarumycin P3 Reverses Mrr1-Mediated Azole Resistance by Blocking the Efflux Pump Mdr1

Published:2022-03-15 Issue:3 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Song Minghui¹,Zhang Ming²,Lu Jinghui¹,Xie Fei³,Song Jintong¹,Luan Xiaoyi¹,Hou Xuben⁴,Lou Hongxiang¹,Chang Wenqiang¹^ORCID

Affiliation:

1. Department of Natural Product Chemistry, Key Laboratory of Chemical Biology, Ministry of Education, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China

2. Institute of Medical Science, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China

3. Department of Pharmacy, Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China

4. Department of Medicinal Chemistry, Key Laboratory of Chemical Biology, Ministry of Education, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, China

Abstract

Palmarumycin P3 (PP3) reduces fluconazole-induced MDR1 transcription to reverse azole resistance in clinical Candida strains. Here, we demonstrated that PP3 restores the susceptibility to several antifungal drugs for Candida albicans strains with gain-of-function mutations in the transcription factor Mrr1.

Funder

Natural Science Fund for Excellent Young Scholars of Shandong Province of China

Young Scholars Program of Shandong University

National Natural Science Foundation of China

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.02126-21

Reference18 articles.

1. Candida albicans - Biology, molecular characterization, pathogenicity, and advances in diagnosis and control – An update